2. Signaling Pathways
  3. Neuronal Signaling
  4. Monoamine Oxidase

Monoamine Oxidase

MAO

Monoamine Oxidase

Related Products

PDF 1.35 MB

Monoamine oxidases (MAO) are a family of enzymes that catalyze the oxidation of monoamines. They are found bound to the outer membrane of mitochondria in most cell types in the body. They belong to the protein family of flavin-containing amine oxidoreductases. Monoamine oxidases catalyze the oxidative deamination of monoamines. Oxygen is used to remove an amine group from a molecule, resulting in the corresponding aldehyde and ammonia. Monoamine oxidases contain the covalently bound cofactor FAD and are, thus, classified as flavoproteins. Because of the vital role that MAOs play in the inactivation of neurotransmitters, MAO dysfunction is thought to be responsible for a number of psychiatric and neurological disorders. MAO-A inhibitors act as antidepressant and antianxiety agents, whereas MAO-B inhibitors are used alone or in combination to treat Alzheimer’sand Parkinson’s diseases.

Monoamine Oxidase Isoform Specific Products:

Monoamine Oxidase Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-170573A
    LOXL2-IN-1 tosylate
    		Inhibitor 99.90%
    LOX-IN-5 tosylate (compound 22) is a selective and orally active lysyl oxidase-like 2 (LOXL2) inhibitor with an IC50 of <300 nM. LOX-IN-5 tosylate possess anti-fibrosis properties.
    LOXL2-IN-1 tosylate
  • HY-N0159R
    Paeonol (Standard)
    		Inhibitor
    Paeonol (Standard) is the analytical standard of Paeonol. This product is intended for research and analytical applications. Paeonol is an active extraction from the root of Paeonia suffruticosa, Paeonol inhibits MAO-A and MAO-B with IC50 of 54.6 μM and 42.5 μM, respectively.
    Paeonol (Standard)
  • HY-D0004
    Azure B
    		Inhibitor 99.87%
    Azure B is a cationic dye and the major metabolite of Methylene blue. Azure B is used in making Azure eosin stains for blood smear staining. Azure B is a high-potency, selective and reversible inhibitor of monoamine oxidases (MAO)-A, with IC50s of 11 and 968 nM for recombinant human MAO-A and MAO-B, respectively. Azure B possesses significant antidepressant-like effects.
    Azure B
  • HY-14203
    (R)-Safinamide
    		Inhibitor 99.89%
    (R)-Safinamide, the enantiomer of safinamide (HY-70057), can inhibit MAO-B with an IC50 value of 0.45 μM.
    (R)-Safinamide
  • HY-N4246
    Bacopaside I
    		Inhibitor 99.20%
    Bacopaside I is an orally active aquaporin AQP1 inhibitor and PKC modulator with neuroprotective and anticancer activities. Bacopaside I specifically blocks the water channel and cGMP-gated ion channel activities of AQP1 without affecting AQP4, thereby inhibiting the migration of colon cancer cells expressing AQP1. Bacopaside I activates the Akt pathway by interacting with PI3K, specifically inhibits MAO-A, effectively alleviates neuron necrosis and apoptosis induced by oxygen-glucose deprivation, reduces oxidative stress, and regulates the surface expression of neuroreceptors. When combined with Bacopaside II (HY-N6016), Bacopaside I significantly reduces the viability, proliferation and invasion ability of breast cancer cells, and binds to the pregnane X receptor (PXR). Bacopaside I is applicable to the research of colon cancer, breast cancer, vascular dementia, cerebral ischemia and other related diseases.
    Bacopaside I
  • HY-14201
    Lazabemide
    		Inhibitor 99.95%
    Lazabemide (Ro 19-6327) is a selective, reversible inhibitor of monoamine oxidase B (MAO-B) (IC50=0.03 μM) but less active for MAO-A (IC50>100 μM). Lazabemide ?inhibits monoamine uptake at high concentrations, the IC50 values are 86 μM, 123 μM and >500 μM for noradrenalin, serotonin and dopamine uptake, respectively. Lazabemide can be used for the research of parkinson and?alzheimer′s disease.
    Lazabemide
  • HY-114520
    TT01001
    		Inhibitor 99.38%
    TT01001 is a selective and orally active mitoNEET agonist and a monoamine oxidase B (MAO-B) inhibitor (IC50 = 8.84 μM). TT01001 does not activate PPARγ but interacts with MitoNEET. TT01001 attenuates oxidative stress and neuronal apoptosis by preventing mitoNEET-mediated mitochondrial dysfunction. TT01001 improves type II diabetes and ameliorates mitochondrial function of mice. TT01001 can used for the studies of type II diabetes and neurological disorders .
    TT01001
  • HY-130242
    PXS-5120A
    		98.12%
    PXS-5120A is a potent, irreversible fluoroallylamine inhibitor of Lysyl Oxidase-like 2/3 (LOXL2/3) with anti-fibrotic activity. PXS-5120A is >300-fold selective for LOXL2 (Ki of 83 nM; pIC50 of 8.4) over LOXL (pIC50 of 5.8).
    PXS-5120A
  • HY-B1413
    Eprobemide
    		Inhibitor 99.62%
    Eprobemide is a non-competitive reversible inhibitor of monoamine oxidase A.
    Eprobemide
  • HY-N0505
    Rosiridin
    		Inhibitor 99.78%
    Rosiridin inhibits MAO A and MAO B with potential beneficial effect in depression and senile dementia. Rosiridin shows an inhibition of 83.8% against MAO B at 10 μM (pIC50=5.38).
    Rosiridin
  • HY-13779A
    J147
    		Inhibitor 99.90%
    J147 is an exceptionally potent, orally active, neuroprotective agent for cognitive enhancement. J147 can pass the blood brain barrier (BBB). J147 can inhibit monoamine oxidase B (MAO B) and the dopamine transporter. J147 plays an impotant role in Alzheimer’s disease (AD).
    J147
  • HY-127109A
    Tisolagiline monomethylsulfate
    		Inhibitor 99.83%
    Tisolagiline methylsulfate (KDS2010) is the selective, reversible and orally active inhibitor for MAO-B with an IC50 of 8 nM. Tisolagiline methylsulfate exhibits neuroprotective and anti-neuroinflammatory activities.
    Tisolagiline monomethylsulfate
  • HY-B1558A
    Bifemelane hydrochloride
    		Inhibitor 99.86%
    Bifemelane hydrochloride (MCI-2016) is a potent, selective and competitive inhibitor of monoamine oxidase A (MAO-A), with a Ki of 4.20 μM. Bifemelane hydrochloride also inhibits MAO-B noncompetitively with a Ki of 46.0 μM. Bifemelane hydrochloride has a potent antidepressant activity and can be used for the research of cognitive and emotional disturbances related to cerebrovascular disease.
    Bifemelane hydrochloride
  • HY-144635
    Nrf2-ARE/hMAO-B/QR2 modulator 1
    		Inhibitor 98.42%
    Nrf2-ARE/hMAO-B/QR2 modulator 1 is a Resveratrol-based multitarget-directed ligands with IC50s of 8.05, 9.83 and 0.57 μM for hMAO-B, NRF2 and QR2. Nrf2-ARE/hMAO-B/QR2 modulator 1 has neuroprotection, decreasing ROS production in okadaic acid-treated mice hippocampal slices. Nrf2-ARE/hMAO-B/QR2 modulator 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Nrf2-ARE/hMAO-B/QR2 modulator 1
  • HY-14196
    Toloxatone
    		Inhibitor 98.11%
    Toloxatone (MD 69276) is a reversible, selective MAO-A inhibitor that can cross the blood-brain barrier. Toloxatone increases the levels of serotonin (5-HT) and norepinephrine in the brain. Toloxatone reduces the immobility time in the forced swimming test in mice, inhibits killing behavior in rats without causing sedation, and shows a correlation between its free plasma concentration and cerebrospinal fluid concentration. Toloxatone is widely used in research related to depression, depressive disorders and Parkinson's disease.
    Toloxatone
  • HY-B0886
    Iproniazid phosphate
    		Inhibitor 99.92%
    Iproniazid phosphate is an orally active, irreversible, non-selective monoamine oxidase (MAO) inhibitor. Iproniazid phosphate inhibits MAO activity and enhances Rotenone (HY-B1756)-induced Apoptosis. Iproniazid phosphate modulates neurotransmitter levels, affects neuronal function, induces hepatic necrosis, and interferes with the endocrine system. Iproniazid phosphate can be used in the research of depression, Parkinson's disease, and hepatotoxicity.
    Iproniazid phosphate
  • HY-10400
    Ladostigil hemitartrate
    		Inhibitor 98.90%
    Ladostigil (TV-3326) hemitartrate is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO) that can cross the blood-brain barrier, with IC50s of 37.1 and 31.8 μM for MAO-B and AChE, respectively. Ladostigil hemitartrate exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil hemitartrate can be used for the research of depression and Alzheimer's disease. Ladostigil (hemitartrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Ladostigil hemitartrate
  • HY-117173
    (Rac)-Rasagiline
    		Inhibitor
    (Rac)-Rasagiline (AGN1135) is the racemate of Rasagiline. (Rac)-Rasagiline is a selective type B MAO (MAO-B) inhibitor. (Rac)-Rasagiline can be used for Parkinson's disease research. (Rac)-Rasagiline protects against MPTP (HY-15608)-induced toxicity.
    (Rac)-Rasagiline
  • HY-101392A
    Harmane hydrochloride
    		Inhibitor 99.88%
    Harmane hydrochloride is a benzodiazepine receptor inhibitor (IC50=7 μM), with IC50 values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane hydrochloride inhibits the I1 imidazoline receptor (IC50 = 30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane hydrochloride inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane hydrochloride can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF).
    Harmane hydrochloride
  • HY-W655727
    (-)-2-Phenylpropylamine
    		Inhibitor 98.44%
    (-)-2-Phenylpropylamine ((S)-2-Phenylpropylamine) (compound 3b) is a MAO-A and MAO-B inhibitor with Ki values of 584 μM and 156 μM, respectively.
    (-)-2-Phenylpropylamine
Cat. No. Product Name / Synonyms Application Reactivity
Monoamine Oxidase Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.